{"title":"体内 CAR T 细胞进入临床试验阶段","authors":"Asher Mullard","doi":"10.1038/d41573-024-00150-z","DOIUrl":null,"url":null,"abstract":"Drug developers want to reprogramme immune cells directly in the body, opening up new gene therapy frontiers in cancer and autoimmunity. Drug developers want to reprogramme immune cells directly in the body, opening up new gene therapy frontiers in cancer and autoimmunity.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":null,"pages":null},"PeriodicalIF":122.7000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"In vivo CAR T cells move into clinical trials\",\"authors\":\"Asher Mullard\",\"doi\":\"10.1038/d41573-024-00150-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Drug developers want to reprogramme immune cells directly in the body, opening up new gene therapy frontiers in cancer and autoimmunity. Drug developers want to reprogramme immune cells directly in the body, opening up new gene therapy frontiers in cancer and autoimmunity.\",\"PeriodicalId\":19068,\"journal\":{\"name\":\"Nature Reviews. Drug Discovery\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":122.7000,\"publicationDate\":\"2024-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews. Drug Discovery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/d41573-024-00150-z\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews. Drug Discovery","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/d41573-024-00150-z","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
Drug developers want to reprogramme immune cells directly in the body, opening up new gene therapy frontiers in cancer and autoimmunity. Drug developers want to reprogramme immune cells directly in the body, opening up new gene therapy frontiers in cancer and autoimmunity.
期刊介绍:
Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena.
Each issue includes:
Highest-quality reviews and perspectives covering a broad scope.
News stories investigating the hottest topics in drug discovery.
Timely summaries of key primary research papers.
Concise updates on the latest advances in areas such as new drug approvals, patent law, and emerging industry trends and strategies.